UGN-102原发性化学消融治疗低级别中危非肌层浸润性膀胱癌的2b期试验
Optima II是一项2b期开放标签单臂试验,评估含丝裂霉素反向热凝胶UGN-102作为低级别中危非肌层浸润性膀胱癌原发化学消融替代经尿道膀胱肿瘤电切术的疗效与安全性。63例患者每周灌注一次共6次,3个月完全缓解率为65%,缓解者12个月无病生存率61%。常见不良事件包括排尿困难、尿频、血尿等。
要点
- UGN-102每周灌注6次,3个月完全缓解率达65%
- 缓解者6、9、12个月无病生存率分别为95%、73%、61%
- 常见不良事件为排尿困难、尿频、血尿、尿急、尿路感染和乏力
核心结论
- UGN-102非手术原发化学消融治疗低级别中危非肌层浸润性膀胱癌可获得显著且持久的治疗反应,可能为反复手术的患者提供替代选择。
研究设计与样本
- 前瞻性、2b期、开放标签、单臂试验,纳入活检证实的低级别中危非肌层浸润性膀胱癌患者,接受6次每周一次的UGN-102灌注。
- 共63例患者(38例男性,25例女性,33-96岁)接受至少1次灌注。
- 主要终点为治疗开始后3个月的完全缓解率,定义为内镜检查阴性、细胞学阴性且目标活检阴性。
主要发现
- 41例(65%)在3个月达到完全缓解。
- 达到完全缓解的患者中,39例(95%)、30例(73%)和25例(61%)在治疗开始后6、9和12个月分别保持无病。
- 共13例患者记录到复发。
- 完全缓解后9个月(治疗开始后12个月)持久缓解概率经Kaplan-Meier分析估计为73%。
- 常见不良事件(发生率≥10%)包括排尿困难、尿频、血尿、尿急、尿路感染和乏力。
临床怎么用
- 对于低级别中危非肌层浸润性膀胱癌患者,UGN-102原发化学消融可作为替代反复经尿道膀胱肿瘤电切术的非手术选择。
- 治疗前需活检证实为低级别中危非肌层浸润性膀胱癌,治疗后3个月评估完全缓解,达缓解者应每季度随访至12个月评估持久性。
局限性
- 单臂设计,无对照,样本量较小(63例),随访至12个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG IR NMIBC) is a recurrent disease, thus requiring repeated transurethral resection of bladder tumor under general anesthesia. We evaluated the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, as a primary chemoablative therapeutic alternative to transurethral resection of bladder tumor for patients with LG IR NMIBC. MATERIALS AND METHODS: This prospective, phase 2b, open-label, single-arm trial recruited patients with biopsy-proven LG IR NMIBC to receive 6 once-weekly instillations of UGN-102. The primary end point was complete response (CR) rate, defined as the proportion of patients with negative endoscopic examination, negative cytology and negative for-cause biopsy 3 months after treatment initiation. Patients with CR were followed quarterly up to 12 months to assess durability of treatment effect. Safety and adverse events were monitored throughout the trial. RESULTS: A total of 63 patients (38 males and 25 females 33-96 years old) enrolled and received ≥1 instillation of UGN-102. Among the patients 41 (65%) achieved CR at 3 months, of whom 39 (95%), 30 (73%) and 25 (61%) remained disease-free at 6, 9 and 12 months after treatment initiation, respectively. A total of 13 patients had documented recurrences. The probability of durable response 9 months after CR (12 months after treatment initiation) was estimated to be 73% by Kaplan-Meier analysis. Common adverse events (incidence ≥10%) included dysuria, urinary frequency, hematuria, micturition urgency, urinary tract infection and fatigue. CONCLUSIONS: Nonsurgical primary chemoablation of LG IR NMIBC using UGN-102 resulted in significant treatment response with sustained durability. UGN-102 may provide an alternative to repetitive surgery for patients with LG IR NMIBC.
引用
- Chevli KK, Shore ND, Trainer A, et al. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. J Urol. 2021. PMID: 34433303. doi:10.1097/JU.0000000000002186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。